Title A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Contact CB
Principal Investigator Hong Liu MD
Study Number 221012
Phase3
Summary This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of MLN9708 versus placebo in patients iwth relapsed and/or refractory multiple myeloma (MM) who are treated with lenalidomide and dexamethasone as their standard therapy.
Eligibility See Clinicaltrials.gov listing for current eligibility criteria.